Rekombinanter MS4A1 (Ocrelizumab Biosimilar) Antikörper
Research Grade
Reaktivität: Human
ELISA
Wirt: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- Target
- MS4A1 (Ocrelizumab Biosimilar)
- Antikörpertyp
- Recombinant Antibody
- Reaktivität
- Human
- Wirt
-
Mammalian Cells
- Expressionssystem
- Mammalian cells
- Klonalität
- Monoklonal
- Applikation
- ELISA
- Verwendungszweck
- Ocrelizumab Biosimilar - Anti-MS4A1, CD20 mAb
- Produktmerkmale
- Antibody Type: IgG1-nd
- Aufreinigung
- Recombinant antibody expressed in mammalien cells and purified.
- Güteklasse
- Research Grade
- Isotyp
- IgG1
-
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Buffer
- PBS pH 7.5
- Lagerung
- -80 °C
- Informationen zur Lagerung
- store at -80°C
-
- Target
- MS4A1 (Ocrelizumab Biosimilar)
- Substanzklasse
- Biosimilar
- Hintergrund
-
2H7
Ocrelizumab is a CD20-directed cytolytic antibody, which is suitable for the treatment of patients with relapsed or primary progressive multiple sclerosis. It is a second-generation recombinant humanized monoclonal antibody of isotype IgG1 that can selectively target B lymphocytes expressing CD20 antigen. Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system, which can cause neurological dysfunction. Most patients with MS experience recurrent episodes with functional deterioration, followed by recovery or remission. - CAS-Nummer
- 637334-45-3
-
Sie sind hier:
